1. Market Research
  2. > Pathology
75 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

Vaginal Cancer - Pipeline Review, H1 2020

  • $ 2000
  • May 2020
  • 381 pages

It is in Phase I stage of development for diffuse large B cell lymphoma and high-grade B cell lymphoma.

  • Lung Cancer
  • Lymphoma
  • Sexually Transmitted Disease
  • United States
  • GlaxoSmithKline plc

Pharmaceutical Drug Delivery Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Route of Administration ; Application ; End User, and Geography

  • $ 4550
  • May 2020
  • 197 pages

Pfizer Inc. has received the European Commission (EC) for its Lorviqua for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced nonsmall cell lung cancer (NSCLC).

  • Lymphoma
  • Pharmaceutical
  • Forecast
  • Market Size
  • GlaxoSmithKline plc

Global Chemotherapy Drugs Market - Opportunities and Forecast (2013-2023)

  • $ 2200
  • March 2019
  • 200 pages

Lymphoma Gastrointestine Others Figure ##: Types of cancer for which clinical trials using chemotherapy drugs treatment are being conducted ##% ##% ##% ##% ##% ##% ##% ##% ##% ##% ##% ##% ##% ##% ##% Source: U. S Clinical Trials Registry GLOBAL THERAPEUTIC CHEMOTHERAPY DRUGS MARKET FIGURE ##: GLOBAL

  • Cancer
  • Chemotherapy
  • Lymphoma
  • Therapy
  • GlaxoSmithKline plc

Vaginal Cancer - Pipeline Review, H2 2019

  • $ 2000
  • December 2019
  • 351 pages

It is in Phase I stage of development for diffuse large B cell lymphoma and high-grade B cell lymphoma.

  • Cancer
  • Lung Cancer
  • Lymphoma
  • United States
  • GlaxoSmithKline plc

Global CML Market Report - 2022

  • $ 3849
  • June 2018
  • 82 pages

Imatinib mesylate is licensed as a firstline treatment for adults with chronic-phase Ph+ CML, and for the management of GIST, and as salvage therapy for Ph+ acute lymphoblastic lymphoma.

  • Lymphoma
  • Therapy
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Merck & Co., Inc.

Europe Pharmaceutical Drug Delivery Market Forecast to 2027 - Covid-19 Impact and Regional Analysis By  Route of Administration ; Application ; End User ; and Country

  • $ 3000
  • June 2020
  • 145 pages

Novartis has received the US Food and Drug Administration (FDA) approved for the Zykadia, which is used for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)positive.

  • Lymphoma
  • Pharmaceutical
  • Forecast
  • GlaxoSmithKline plc
  • Merck & Co., Inc.

Global Regenerative Medicine Market 2018-2022

  • $ 2500
  • April 2018
  • 134 pages

Approximately ##% of clinical trials of regenerative medicine are being conducted in oncology indications such as leukemia, lymphoma, brain cancer, breast cancer, bladder cancer, cervix cancer, colon cancer, esophageal cancer, ovarian cancer, and pancreatic cancer.

  • Lymphoma
  • Regenerative Medicine
  • GlaxoSmithKline plc
  • MiMedx Group, Inc.
  • Organogenesis, Inc.

Axillary Hyperhidrosis - Pipeline Review, H1 2020

  • $ 2000
  • March 2020
  • 53 pages

The Merger would create a pharmaceutical company focused on developing novel and differentiated prescription therapies addressing unmet patient needs in hyperhidrosis, cutaneous Tcell lymphoma, psoriasis, and other debilitating dermatologic disorders.

  • Dermatological Condition
  • Therapy
  • United States
  • Allergan plc
  • GlaxoSmithKline plc

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Saudi Arabia

  • $ 1995
  • August 2019
  • 140 pages

GSK discontinued the global development of GSK-## in Phase I development for relapsed or refractory small-cell lung cancer, and GSK-## in Phase I stage of development for follicular lymphoma, diffuse large B-cell lymphoma, solid tumors, and refractory multiple myeloma.

  • Lymphoma
  • Medical Device
  • Pharmaceutical
  • Saudi Arabia
  • GlaxoSmithKline plc

Immuno-oncology: Focus on Developments and Opportunities in Immune Checkpoint Modulators

  • $ 7995
  • March 2020
  • 141 pages

In the long term, GlobalData anticipates ICIs having more prominence in the treatment of malignancies such as HL, MM, AML, and other types of lymphomas.

  • Lymphoma
  • Therapy
  • China
  • United States
  • GlaxoSmithKline plc

Global Marine Pharmaceuticals Market 2018-2022

  • $ 2500
  • March 2018
  • 108 pages

Even today, cytarabine is one of the most widely used compounds for treating individuals with relapsed aggressive lymphomas and acute myeloid leukemia (AML).

  • Lymphoma
  • Pharmaceutical
  • GlaxoSmithKline plc
  • PharmaMar SA
  • Seattle Genetics, Inc.

Global HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country (2017-2022) – By Region

  • $ 2000
  • March 2018
  • 184 pages

Executive Summary A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the ...

  • Lymphoma
  • Therapy
  • Vaccine
  • Market Size
  • GlaxoSmithKline plc

Global Orphan and Rare Dermatology Drugs Market to 2024 - An Increasingly Competitive Landscape as New Companies Enter the Market with Novel Products, Driving Strong Market Growth

  • $ 4995
  • September 2018
  • 141 pages

However, Humira is packaged with a boxed warning relating to an increased risk of severe infections, such as tuberculosis and bacterial sepsis, and an increased risk of malignancy, such as lymphomas, for patients taking this drug.

  • Autoimmune Disease
  • Dermatological Condition
  • Dermatological Treatment
  • Lymphoma
  • GlaxoSmithKline plc

Global Injectable Drugs Market 2017-2021

  • $ 2500
  • July 2017
  • 84 pages

In January 2017, the FDA approved IMBRUVICA as the first treatment for relapsed/ refractory marginal zone lymphoma.

  • Lymphoma
  • Pathology
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc

Artificial Intelligence Technologies: Market Prospects - Featuring Expert Panel Views from Industry Survey 2018

  • $ 2995
  • March 2018
  • 104 pages

Artificial Intelligence Technologies: Market Prospects - Featuring Expert Panel Views from Industry Survey 2018 Summary Artificial intelligence (AI) is defined as the theoretical and practical application ...

  • Advanced IT
  • Artificial Intelligence
  • Healthcare
  • Pharmaceutical
  • GlaxoSmithKline plc

Anti-Tumor Drugs Companies in China

  • $ 1800
  • October 2019
  • 65 pages

Experience from basic research and long term clinical application has shown that Chapter VII ANTI-TUMOR DRUGS PRODUCER DIRECTORY KLT presents good effect in treatment of cancers mainly at sites of lung, liver, stomach, breast, prostate and malignant lymphoma, etc.

  • Lymphoma
  • Pharmaceutical
  • China
  • GlaxoSmithKline plc
  • Zhejiang Expressway Co., Ltd.

Anti-Tumor Drugs Markets in China

  • $ 4000
  • October 2019
  • 214 pages

SMALL CELL LUNG CANCER, AND OVARIAN CANCER), LYMPHOMAS AND GERM CELL TUMORS.

  • Anti-Infective
  • Lymphoma
  • China
  • East Asia
  • GlaxoSmithKline plc

Global Genetic Disorders Drugs Market to 2023 - A Rapidly Growing Treatment Landscape Driven by Targeted Complement System Inhibitors and Enzyme Replacement Therapies to Treat PNH and Lysosomal Storage Disease

  • $ 4995
  • December 2017
  • 160 pages

They also have an increased risk of Parkinson' s disease, and cancers such as myeloma, leukemia and lymphoma.

  • Clinical Trial
  • Genetic Disorder
  • Lymphoma
  • Therapy
  • GlaxoSmithKline plc

Pharmaceutical Drugs Global Market Report 2018

  • $ 8000
  • March 2018
  • 455 pages

Its importance results from the large population of cancer patients suffering from various types of blood cancers such as leukemia, lymphoma, and myeloma.

  • Healthcare
  • Lymphoma
  • Pharmaceutical
  • Market Size
  • GlaxoSmithKline plc

Global Diabetes Drugs Market to 2023 - A Diversifying Treatment Landscape as GLP-1 Receptor Agonists and SGLT-2 Inhibitors Gain Ground Following Landmark Cardiac Outcomes

  • $ 4995
  • September 2017
  • 137 pages

Numerous intracellular substrates such as insulin receptor substrate (IRS) proteins, casitas B-lineage lymphoma (CBL), adapter proteins with a pleckstrin homology (PH) and Src Homology ## (SH##) domain and GRB##-associated-binding protein ## (GAB##) are activated upon binding of the insulin rece

  • Clinical Trial
  • Diabetes
  • Insulin
  • Lymphoma
  • GlaxoSmithKline plc
View report >

Lymphoma Statistics and Therapy Market in the US - Forecast

  • July 2017
  • 8 pages

The company intends to initiate new combination study in patients with follicular lymphoma in 2017.

  • Lymphoma
  • Therapy
  • United States
  • Epizyme, Inc.
  • GlaxoSmithKline plc

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on